Färber I, Klinger C, Wutzler P, Thiel K D, Reefschläger J, Herrmann G
Acta Virol. 1987 Jan;31(1):13-8.
The effect of (E)-5-(2-bromovinyl)- and 5-vinyl-1-beta-D-arabinofuranosyluracil (BrVaraU, VaraU) in comparison to 9-(2-hydroxyethoxymethyl)guanine (ACV) on the proliferation of human lymphoblastoid P3HR-1 cells in culture and on the expression of Epstein-Barr virus capsid antigen (VCA) in the same cells was evaluated. After 7 days of cell growth, at 100 mumol/l the total number of new generations in drug-treated cultures was similar or 5 and 10% below that in drug-free control cultures, for VaraU, ACV, and BrVaraU, respectively. During the same time the percentage of VCA-expressing cells decreased from 6.3% in drug-free cultures to 1.3, 1.5, and 2.0% in cultures treated with VaraU, ACV and BrVaraU, respectively. In VaraU-treated cultures a further decrease in the percentage of VCA-positive cells down to 0.5% was revealed 7 days after drug removal. VaraU was also effective in reducing the proportion of VCA-expressing cells at 10 and 1 mumol/l. At 14 days after drug removal, the inhibitory effect of ACV was nearly reversed, whereas BrVaraU showed a prolonged VCA- suppressing effect.
评估了（E）-5-（2-溴乙烯基）-和5-乙烯基-1-β-D-阿拉伯呋喃糖基尿嘧啶（BrVaraU、VaraU）与9-（2-羟乙氧基甲基）鸟嘌呤（阿昔洛韦）相比，对培养的人淋巴母细胞样P3HR-1细胞增殖以及同一细胞中爱泼斯坦-巴尔病毒衣壳抗原（VCA）表达的影响。细胞生长7天后，在100μmol/L时，用VaraU、阿昔洛韦和BrVaraU处理的培养物中的新一代总数分别与无药物对照培养物中的相似或比其低5%和10%。与此同时，表达VCA的细胞百分比从无药物培养物中的6.3%分别降至用VaraU、阿昔洛韦和BrVaraU处理的培养物中的1.3%、1.5%和2.0%。在VaraU处理的培养物中，去除药物7天后，VCA阳性细胞百分比进一步降至0.5%。VaraU在10μmol/L和1μmol/L时也能有效降低表达VCA的细胞比例。去除药物14天后，阿昔洛韦的抑制作用几乎逆转，而BrVaraU显示出延长的VCA抑制作用。
